{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-286169","form_type":"8-K","ticker":"IDYA","cik":"0001676725","company_name":"IDEAYA Biosciences, Inc.","filed_at":"2024-12-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.196143+00:00","generated_at":"2026-05-28T22:45:56.938068+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"IDEAYA licenses DLL3 ADC SHR-4849 from Hengrui; total potential payments $1.045B","bullets":["Exclusive worldwide license (ex-Greater China) for Phase 1 DLL3-targeting Topo-I-payload ADC SHR-4849.","Hengrui Pharma eligible for $75M upfront, up to $200M development/regulatory milestones, plus commercial milestones and mid-single to low-double digit royalties.","In 11 evaluable SCLC patients at therapeutic doses, 8 partial responses observed (~73% ORR, including unconfirmed) with manageable safety profile.","IDEAYA targets US IND filing for SHR-4849 in H1 2025; cash runway guided to at least 2028 unchanged.","SHR-4849 offers rational combination opportunity with IDEAYA's Phase 1 PARG inhibitor IDE161 for enhanced preclinical efficacy."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-286169","json":"https://secwatch.observer/filing/0001193125-24-286169.json","markdown":"https://secwatch.observer/filing/0001193125-24-286169.md","text":"https://secwatch.observer/filing/0001193125-24-286169.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1676725/000119312524286169/0001193125-24-286169-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1676725/000119312524286169/d917390d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T22:45:56.938068+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}